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A retrospective seroepidemiologic study was performed to examine the association between human papillomaviruses (HPV) 16
infection and carcinomas of the oropharynx, the oesophagus, penis and vagina. Sera were selected from the serum bank from the
Antoni van Leeuwenhoek Hospital (Netherlands Cancer Institute) and the Slotervaart Hospital in Amsterdam, the Netherlands.
Presence of HPV 16 specific antibody was assessed using HPV 16 L1 capsids. Sera positive for HPV 16 capsid antibody were further
tested for antibody against HPV 16 E7 peptides. Prevalence of antibody against HPV 16 L1 capsids among both the negative control
group without cancer and the negative control group with gastric cancer was 18%, while seroprevalence among the control group of
patients with HPV-associated cervical squamous cell carcinoma was 47% (Po0.001). Among the patients with penile squamous cell
carcinoma seroprevalence was 38% (Po0.001), among patients with oropharyngeal carcinoma 33% (P¼0.04) and among patients
with oesophageal squamous cell carcinoma 14% (P¼0.7). The serological evidence for association between HPV 16 infection and
both oropharyngeal carcinoma and penile carcinoma was established. The conclusion that no association was found between the
presence of antibody against HPV 16 L1 capsids and oesophageal squamous cell carcinoma was in accordance with results of other
studies carried out in the Netherlands using HPV DNA technology. In the subjects with HPV 16 L1 capsid antibody, no association
was found between the antibody against HPV 16 E7 and clinical outcome.
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The causative association between infection with oncogenic human
papillomaviruses (HPV) and cervical squamous cell carcinoma has
been established by molecular and epidemiological studies (Mun ˜oz
and Bosch, 1989; zur Hausen, 1994). Current infection by HPV can
be detected by polymerase chain reaction (PCR) or hybrization
techniques. Human papillomavirus serology can be applied to
determine past or present HPV infection (de Villiers, 1992;
Kirnbauer et al, 1994). Serological assays based on HPV capsids,
which represent conformational viral epitopes, can detect HPV-
type restricted antibodies. These assays have been validated as
useful tools for seroepidemiologic studies among various cohorts
(Van Doornum et al, 1994, 1998; Dillner, 1995; Nonnenmacher
et al, 1995, 1996; Wideroff et al, 1995, 1996a; Wikstro ¨m et al,
1995a,b; Lehtinen et al, 1996).
Results of some studies suggest that HPV infection may be a risk
factor for squamous cell carcinoma of the head and neck or
encompasses a distinct entity with an increased sensitivity to
radiotherapy (Gillison et al, 2000; Forastiere et al, 2001; Lindel et al,
2001; Mork et al, 2001). Squamous cell oesophageal cancer shows
wide regional variation in incidence and causal association (Sur
and Cooper, 1998). With regard to the association between HPV
infection and oesophageal squamous cell carcinoma, contradictory
molecular and serological findings are reported (Dillner et al, 1995;
Bjørge et al, 1997b; Kok et al, 1997; Miller et al, 1997; Saegusa et al,
1997; de Villiers et al, 1999; Lagergren et al, 1999; Lavergne et al,
1999). For the Netherlands, that are reported to be a low-risk area
for squamous cell cancer of the oesophagus, using HPV DNA
technology no evidence was found for a role of HPV as a causative
agent (Kok et al, 1997). However, while detection of HPV DNA
determines only current infection, an advantage of serological
studies is that they can give insight into exposure to papilloma-
viruses in the past.
Presence of HPV DNA in carcinomas of the penis is observed in
a proportion of the specimens analysed (Grussendorf-Cronen,
1997; Tornesello et al, 1997; Dianzani et al, 1998; Levi et al, 1998;
Poblet et al, 1999; Dillner et al, 2000; Rubin et al, 2001). Some
serological studies relative to HPV infection in individuals with
penile carcinoma were carried out in relatively small groups of
patients (Wideroff et al, 1996b; Strickler et al, 1998; Carter et al,
2001).
With regard to vaginal and vulvar cancer, little is known about
the prevalence of antibody against HPV among patients with these
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ycancers, although HPV infection is considered as a risk factor for
vaginal cancer (Daling et al, 2002).
The objective of this retrospective study was to determine the
seroprevalence of antibody against HPV 16 viral-like particles
(VLP) containing L1 proteins among Dutch patients with
carcinomas in the oropharyngeal region, tongue and larynx,
patients with oesophageal carcinoma, women with vaginal
carcinoma and men with penile carcinoma. Sera positive for
antibody against HPV 16 L1 were tested for the presence of
antibody to E7.
MATERIALS AND METHODS
Serum specimens were taken from the serum bank at the Antoni
van Leeuwenhoek (AvL) Hospital and Netherlands Cancer Institute
in Amsterdam, the Netherlands. Cases were selected over a period
of 10 years, 1989–1999, based on the diagnosis as stated in the
anonymised medical records. The inclusion criterion was the site
of the cancer: penis, cervix, vagina, the upper aerodigestive tract
(larynx, oropharynx, tongue), oesophagus and stomach. The
anatomical sites were defined according to the codes of the
International Classification of Diseases (WHO, 1979). Sera from
patients with cervical squamous cell carcinoma were considered as
HPV-positive cancer control sera. Sera from patients with gastric
carcinoma were considered as HPV-negative cancer control sera.
For the HPV-negative control group without cancer, serum
specimens were selected from the serum bank in the Slotervaart
(SL) hospital. These serum specimens were obtained from patients
referred to the gastroenterology clinic for gastric ulcer complaints
during 1999. The control group was matched on gender and age
with the gastric carcinoma cases.
The sera from the AvL patients were obtained at the first visit to
the hospital during the period wherein the diagnosis was made.
The sera from the SL hospital patients were also taken at the first
visit to the gastroenterology clinic. The specimens were stored at
 201C and transported on dry ice to the Karolinska Institute,
where the assays were performed by CM Korse and JCGM Buning-
Kager.
The pathological diagnosis was made at the Department of
Pathology of the AvL hospital and the SL hospital, respectively,
using standard methods, and coded according to international
standards (WHO, 1979).
First, all sera were screened on the presence of IgG antibody
against HPV 16 capsids containing L1 proteins. The positive sera
were further tested on the presence of IgG antibody against HPV
16 E7 peptides.
Enzyme-linked immunosorbent assays
Baculovirus-expressed HPV16 capsids containing both the L1
proteins were diluted in cold phosphate-buffered solution (PBS) to
1mgml
 1, coated overnight at 41C onto microtiter plates and
subsequently blocked with 10% horse serum in PBS (HS-PBS). Sera
were diluted 1:30 with HS-PBS and added to the plates for 2h at
room temperature (RT). A mouse monoclonal antibody to human
IgG, diluted 1:800, was added and incubated for 90min at room
temperature, followed by a horseradish peroxidase-conjugated
antibody to mouse IgG. Before every addition, the plates had been
washed with PBS-0.1% Tween. For each sample the absorbency of
the same sample obtained from a well coated with disrupted
bovine papilloma virus (BPV) was subtracted from the absorbency
obtained for the corresponding well coated with HPV 16 capsids.
The assays included two internal positive and one negative
control specimens on each ELISA plate. Three pools of sera from
patients with cervical carcinoma, from patients with cervical
intraepithelial neoplasia (CIN) and from healthy blood donors
were used for this purpose. The absorbencies read from each plate
were normalised relative to the results of the internal standard. The
internal standard was measured in a plate with negative control
sera obtained from sexually inexperienced women. Cutoff level was
defined as the mean value of the absorbencies of the plate with the
negative controls plus three standard deviations.
For the measurement of E7 peptides the same protocol was used.
The only difference was that the peptide was diluted to 1mgml
 1
in Tris buffer and coated overnight at room temperature. As
negative control another plate was coated with Tris buffer only.
The E7 peptide has the designation E7-2 and has the amino-acid
sequence PETTDLYCYEQLNDSSEEED (Dillner, 1990).
Data analysis
The data were analysed using the Statistical Package for Social
Science (SPSS/PC Version 10.0.5) and Epi Info Version 6.0 (Dean
et al, 1994). To compare the proportions the w
2 method was used,
and Fisher’s exact test when appropriate. A two-tailed P-value of
less than 0.05 was considered to indicate statistical significance.
RESULTS
The characteristics such as gender and age of the patients from
whom the serum specimens were obtained are presented according
to pathological diagnosis in Table 1. The seroprevalence of
antibody to HPV 16 L1 capsids among the various groups is
shown in Table 2. The sera positive for antibody against HPV 16 L1
Table 1 Characteristics of 606 patients with various carcinomas and 100 patients selected as negative control group
N Mean age (years) Male Mean age (male) Female Mean age (female)
Negative control (no cancer) 100 61.8 50 61.3 50 62.4
Negative control (stomach carcinoma) 54 61.5 37 61.2 17 62.3
Cervical squamous carcinoma 51 63.7 51 63.7
Tongue carcinoma 56 58.7 30 59.1 26 58.3
Oropharyngeal carcinoma 48 56.1 33 57.2 15 53.8
Oesophageal carcinoma 117 64.5 86 63.8 31 66.5
Squamous cell carcinoma 56 64.9 34 64.6 22 65.5
Adenocarcinoma 48 64.4 41 63.1 7 71.6
Others 13 63.2 11 63.7 2 60.6
Laryngeal carcinoma 127 62.1 111 62.7 16 58.0
Vaginal carcinoma 31 71.5 31 71.5
Penile carcinoma 122 60.9 122 60.9
Total 706 61.9 417 61.3 228 62.9
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to HPV 16 E7 peptides; the results are also shown in Table 2.
The seroprevalence found in the negative control groups was 18%
both in the stomach cancer control group (10 out of 54) and in
the noncancer gastric ulcer group (18 out of 100).
The seroprevalence in the cervical squamous cell cancer group
was 47% (24 out of 51); the difference with the negative
control group was statistically significant (Po0.001). A total
of 46 of the 122 (38%) individuals with penile cancer were
positive for HPV 16 L1 antibody (Po0.001). The proportion of
individuals with oesophageal squamous cell carcinoma with
antibody against HPV 16 L1 capsids was only 14% (8/56), whereas
11 of the 48 (23%) sera from patients with oesophageal
adenocarcinoma were positive for HPV 16 L1 antibody. In the
group of patients with oropharyngeal carcinoma, 16 out of
48 (33%) individuals were positive for antibody against HPV 16
L1 antibody (P¼0.04). The seroprevalence found in the patients
with tongue carcinoma or laryngeal cancer was 12 out of 56 (21%)
and 25 out of 127 (20%), respectively. A total of 8 out of 31 (26%)
of the patients with vaginal carcinoma were positive (P¼0.47). In
the negative control sera that were positive for HPV 16 L1
antibody, two of 27 (7%) sera were also positive for antibody
against HPV 16 E7 peptides, and seven of the 24 (29%) of the sera
from patients with cervical squamous cell carcinoma, who were
considered as positive control group (P¼0.07, Fisher’s exact two-
tailed). No statistically significant difference was observed for the
presence of HPV 16 E7 antibody in any of the other groups
studied.
In the group of patients with cervical carcinoma and penile
carcinoma, the possible association between clinical outcome and
presence of antibody both against L1 capsids and E7 peptide
was analysed. As clinical outcome the following categories were
chosen: alive with or without tumour and died with or without
tumour. For 21 of the 24 subjects with cervical carcinoma, who
were positive for HPV 16 L1 antibodies and in whose serum
samples antibody against E7 was determined, the follow-up data
were available. There were no statistical differences between the
subjects with or without antibodies against E7 with regard to
survival (P¼0.21, Fisher’s exact test, two-sided). The same
analysis was executed for the subjects with penile carcinoma,
again no differences could be found (P¼1.0, Fisher’s exact test,
two-sided).
DISCUSSION
In this study, we analysed the prevalence of HPV 16 specific
antibody in patients with a variety of cancers. As HPV seropositive
cancer control subjects were included patients with cervical
squamous cell carcinoma, and patients with gastric ulcer or
stomach carcinoma as HPV negative control patients without and
with cancer, respectively.
We realise that a retrospective, seroepidemiological study using
hospital-based negative control subjects has some limitations in
comparison with a nationwide seroepidemiological case–control
study or prospective studies as carried out in the Nordic countries
to study the association between oesophageal carcinoma and HPV
antibody positivity (Dillner et al, 1995; Bjørge et al,1 9 9 7 a , b ;
Lagergren et al, 1999). Nevertheless, results of a retrospective case–
control study can be used to determine disease aetiology.
Furthermore, the number of case subjects in the various subgroups
in our study was relatively large. A problem arises in the selection of
the control subjects, as these were taken from the hospital
population on practical considerations. Therefore, we included a
negative control group without cancer as well as a control group
with cancer that is not considered to be caused by an HPV infection.
The seroprevalence of 18% for HPV 16 antibody in the HPV-
negative control groups in our study seemed rather high, but could
be considered consistent with figures reported previously from
The Netherlands. In Dutch patients who were HPV DNA negative
and participated in Amsterdam, The Netherlands, in a noninter-
vention study relative to cervical dysplasia a seroprevalence of
14.6% was reported (Bontkes et al, 1999). In studies on HPV
seroprevalence among heterosexuals with multiple partners, we
found previously a frequency of 23 and 20% of IgG antibody
against HPV 16 L1 peptides and HPV 16 L1 VLP, respectively (Van
Doornum et al, 1994, 1998).
Seroprevalences must be compared with local or regional figures
as the values can differ in different groups of subjects living in
various countries. In a study described by Wideroff et al (1999)
seroprevalence for HPV 16 IgG antibody among cases with
squamous intraepithelial lesions (SIL) was 51.3% and for the
random control group the seroprevalence for HPV 16 was 15.9%.
On the other hand, among high-risk populations in Greenland and
Denmark, 56.2% of the Greenlander women and 41.1% of the
Danish women were found positive for antibody to HPV 16
Table 2 Results of antibody testing against HPV 16 L1 capsids in 606 patients with various carcinomas and results of antibody testing against HPV 16 E7
peptides assay carried out in the HPV 16 L1 capsid antibody positive samples
N HPV 16 pos Pos/N (%) P-value
a OR
b E7 Pos/N (%)
Negative control (no cancer) 100 18/100 (18) 2/18 (11)
Negative control (stomach carcinoma) 54 10/54 (18) 0/9 (0)
Cervical squamous carcinoma 51 24/51 (47) o0.001 4.00 7/24 (29)
(1.9–8.4)
Tongue carcinoma 56 12/56 (21) 0.741 3/12 (25)
Oropharyngeal carcinoma 48 16/48 (33) 0.043 2.25 2/16 (12)
(1.0–4.9)
Laryngeal carcinoma 127 25/127 (20) 0.876 3/25 (12)
Oesophageal carcinoma 117 20/117(17) 0/20 (0)
Squamous cell 56 8/56 (14) 0.649
Adenocarcinoma 48 11/48 (23)
Others 13 1/13 (8)
Vaginal carcinoma 31 8/31 (26) 0.466 0/8 (0)
Penile carcinoma 122 46/122 (38) o0.001 2.72 5/45 (11)
(1.5–4.9)
Total 706 179/706(25) 22/177(12)
aYates corrected.
bOdds ratio (95% confidence limits).
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South Africa among San people, also known as Bushmen,
seroreactivity to HPV 16 was 16.1% among adults (Marais et al,
2000).
Oropharyngeal carcinoma
The seroprevalence for patients with oropharyngeal cancer of 33%
(16 out of 48) in the present study is comparable with the
prevalence of 38% (10 out of 26) vs 10% (14 out of 137) among
control subjects reported in a recently published nested case–
control study among patients with head and neck cancers in the
Nordic countries (Mork et al, 2001). In that study a significant
relation was also found between seropositivity for HPV 16
antibody and cancers originating from mucosal stratified squa-
mous cell epithelium in the head and neck region. In another
study, the authors suggested a causative association between HPV
and a subset of squamous cell cancers of head and neck, more
case–control studies were considered to be needed to assess that
interaction (Franceschi et al, 2000; Gillison et al, 2000).
Tongue and laryngeal carcinomas
Although the prevalence of 21% for positivity of HPV 16 antibody
among patients with tongue cancer found in the present study was
greater than the 16% found in the study of Mork, we could not
conclude that there was an association between presence of HPV
antibody and tongue cancer because the proportion of HPV 16
seropositive control subjects was higher in the present study than
among the control patients studied by Mork, 18 vs 7% (Mork et al,
2001). The same goes for the figures found for the HPV 16
seroprevalence among the patients with laryngeal cancers.
Oesophageal carcinoma
In the present study conducted among Dutch patients, we did not
find an association between positivity for HPV 16 antibody and
oesophageal carcinoma. This is in accordance with other studies as
reported by Lagergren et al (1999). In the past, prospective
seroepidemiological evidence had been brought forward that HPV
16 infection might be a risk factor for oesophageal carcinoma in
Norway and Finland (Dillner et al, 1995; Bjørge et al, 1997a,b).
Contrary to these findings, the seroepidemiologic case–control
study later performed by Lagergren et al (1999) in Sweden could
not support the conclusions from the above-mentioned studies. It
must be noted that in various studies, the seroprevalence among
the control subjects differ. For example, in the study in which
Bjørge reported an association between HPV 16 seropositivity and
oesophageal cancer, the seroprevalence for HPV 16 in patients with
oesophageal squamous cell carcinoma was 12 vs 5% in the
controls. In the study reported by Dillner (1995) among Finnish
patients with oesophageal carcinoma, the seroprevalence of
antibody against HPV 16 was 21 vs 3% among matched controls.
In the study of Lagergren, seroprevalence of HPV 16 antibody was
11.6% in the case subjects with oesophageal squamous cell
carcinoma, and 10.9% in the control subjects, while in the present
study, the seroprevalence among cases with oesophageal carcino-
ma was 14 vs 18% among the negative control group.
It must be also taken into account that the role of HPV infection
in squamous cell oesophageal cancer shows geographic variation
(Sur and Cooper, 1998). This variation may be because of the fact
that oesophageal carcinogenesis is a complex multistep process.
For instance, in a study among Japanese patients, it was concluded
that HPV was not likely to be involved in oesophageal squamous
cell carcinoma, and in only 10 of 22 Alaska native patients with
squamous cell carcinoma of the oesophagus HPV DNA was
detected (Miller et al, 1997; Saegusa et al, 1997). In Chinese
patients originating from a high-incidence area, HPV DNA was
demonstrated in 20 out of 117 (17%) of the cases (De Villiers et al,
1999). However, only 3 out of 117 (3%) was of the high-risk HPV
type. In a study performed in The Netherlands, no evidence could
be found for a role of HPV in squamous cell carcinoma of the
oesophagus (Smits et al, 1995; Kok et al, 1997). In two other West
European studies performed in Belgium and France, the role of
HPV infection in the pathogenesis of oesophageal squamous cell
carcinoma could also not be demonstrated (Benamouzig et al,
1995; Lambot et al, 2000).
The suggestion was put forward that there might be a difference
between the results from studies executed in high-risk and low-risk
areas for oesophageal carcinoma because of the differing time of
diagnosis of the cancer. Another explanation might be that the
tissue of an early diagnosed oesophageal carcinoma or premalig-
nant papilloma might contain HPV DNA and/or HPV antigens,
and not the specimens obtained from advanced oesophageal
carcinoma. This is by analogy with bovine oesophageal carcinoma
and the association with bovine papillomavirus (BPV) type 4. BPV
4 DNA and antigens can be found in high copy numbers in the
premalignant oesophageal papillomas, but not in the carcinomas.
Cattle infected with BPV 4, which feed on bracken fern, have a high
risk of oesophageal cancer, but the BPV 4 viral genome is not
present in frank cancers or fully transformed cells (Campo, 1992).
If this phenomenon holds true for human oesophageal carcinoma,
we should predict a high seroprevalence for antibody against HPV.
In fact, we did not find a greater prevalence of antibody against
HPV 16 capsids among patients with oesophageal cancer than in
control patients.
Penile carcinoma
Only a few studies are reported on penile cancer and the role of
HPV; a review is given by Griffiths and Mellon (1999) and later by
Dillner et al (2000). The prevalence of subclinical or latent penile
HPV infections among young, sexually active and healthy
individuals is reported between 20 and 50%, while the incidence
of penile carcinoma is relatively low (Van Doornum et al, 1994;
Wikstro ¨m et al, 2000). In penile carcinoma patients from
Argentina, HPV DNA was detected in 27 out of 38 (71%) of the
cases using single-stranded conformational polymorphism; 10 of
the 38 (26.3%) patients were found positive for HPV 16 (Picconi
et al, 2000). The difference with the prevalence of HPV 16 specific
antibody found in the present study might be attributed to
geographical distribution or a specific subtype of penile cancer. In
a study on formalin-embedded tissue samples collected from the
USA and Paraguay using the sensitive SPF 10 primers HPV DNA
was detected in 80% of basaloid and 100% of warty tumour
subtypes, whereas keratinising squamous cell carcinomas and
verruccous carcinomas were positive for HPV DNA in 34.9 and
33.3% of the cases, respectively (Rubin et al, 2001). With regard to
antibody against HPV, one study on the seroprevalence of HPV 16
antibody among Chinese patients with penile cancer reported that
no antibodies against HPV 16 VLPs were detected in serum
specimens of 55 Chinese patients with penile cancer, nor in the
sera of 60 controls (Wideroff et al, 1996b). In an HPV 16
serosurvey of cancer patients, a small subset of eight patients with
penile squamous carcinoma was described with five of them
positive for HPV 16 antibody (Strickler et al, 1998). In a study
from Seattle, a seroprevalence of HPV 16 antibody for in situ
penile cancer of 20.3% was found, and 28.5% for invasive penile
cancer (Carter et al, 2001). Thus, the findings of our study are in
accordance with the latter studies indicating a relation between
HPV infection and penile carcinoma.
Vaginal carcinoma
The elevated HPV 16 seroprevalence among patients with vaginal
cancer was not statistically significant compared to the control
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report that antibodies to HPV 16 L1 were strongly related to the
risk of vaginal cancer (Daling et al, 2002). Approximately 44% of
both the in situ and the invasive case subjects had antibodies to
HPV 16 L1 compared to 15% of the control women.
Antibody against E7
Presence of antibodies against papillomavirus might be used as
prognostic marker in cervical cancer patients (Heim et al, 2002). If
expression of transforming proteins as E6 and E7 is implicated in
the carcinogenesis of epithelial carcinoma, it might be hypothe-
sised that development of antibody against either of these
oncoproteins is related with clinical outcome. Antibody responses
against E6 and E7 proteins have been shown to be associated with
clinical stage of cervical carcinoma (Zumbach et al, 2002). In
control groups of that study a prevalence of 2% was found,
whereas 26 of 95 (27%) patients with cervical carcinoma showed
antibody against HPV 16 E6 or E7. Antibody against HPV 16 E6
was dominant among patients with HPV 16 specific antibody
(23 out of 27, 85%) over that to E7 (9 out of 27, 33%). E6 and/or E7
antibody prevalence increased from 21% in FIGO stage-I patients
to 42% in stage-II patients and reached 52% in stage-III patients.
However, in the present study, among patients with cervical
carcinoma who were HPV 16 L1 antibody positive, a prevalence of
7 out of 24 (29%) was found for antibody against HPV 16 E7
peptides. Analysis of the association between the presence of E7
antibody and the clinical outcome yielded no significant result,
indicating that E7 antibody does not improve clinical outcome.
This finding is in accordance with the conclusion drawn in a study
from Sweden, in which antibodies to HPV 16 capsids and to the
oncoproteins E6 and E7 did not appear to be prognostic indicators
of cervical cancer prognosis (Sillins et al, 2002).
In conclusion, we found evidence for a strong association
between the presence of HPV 16 L1 antibody and both cervical
squamous cell carcinoma and penile squamous cell carcinoma. A
relation between the presence of HPV 16 antibody and orophar-
yngeal cancer was also found. No serological evidence was
demonstrated for an association between HPV 16 antibody and
oesophageal, tongue, laryngeal and vaginal carcinoma.
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